Métastase cérébrale d’un cancer de l’endomètre: à propos d’un cas et une revue de la littérature

Kouhen, Fadila; Afif, Mohammed; Kabous, M. El; Raiss, Fadoua; Benhmidou, Naoual; Majjaoui, Sanaa El; Elkacemi, H.; Kebdani, Tayeb; Benjaafar, Noureddine

doi:10.11604/pamj.2015.20.68.6097

Cited by 4 publications

(11 citation statements)

References 13 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Approximately 70% of the patients who developed BMs from EC had advanced-stage disease (stage III, 37.2% and stage IV, 31.2%) at the time of diagnosis. The histologic type was available in 391 patients [ 6 , 28 , 31 , 37 , 53 , 59 , 62 , 66 , 67 , 74 , 75 , 81 , 87 , 88 , 90 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 106 , 107 , 108 , 109 , 110 , 112 , 113 , 114 , 115 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 131 ], of whom 319 (81.5%) had adenocarcinomas and 74 (18.9%) had unfavorable cancer types, such as carcinosarcoma, leiomyosarcoma, small-cell carcinoma, and undifferentiated carcinoma. BM was...…”

Section: Endometrial Cancermentioning

confidence: 99%

“…BM was more likely to occur in patients with carcinosarcoma and undifferentiated histological type than in the general population of patients with primary endometrial lesion [ 6 ]. Among the 192 patients for whom the histological grade was known, 74.5% had high-grade (Grade 3) disease [ 6 , 20 , 31 , 37 , 81 , 90 , 93 , 94 , 95 , 96 , 98 , 100 , 101 , 102 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 112 , 113 , 114 , 117 , 118 , 121 , 122 , 123 , 124 , 125 , 126 , 128 , 131 ], including 27 cases of serous adenocarcinoma and 5 cases of clear cell adenocarcinoma.…”

Section: Endometrial Cancermentioning

confidence: 99%

“…Around 2010, a substantial decrease in the number of patients with a single BM was observed (68.0% vs. 42.1%), and this was observed for other solid tumors, as described earlier in the CC section. Data on the site of BMs, that is, whether the metastasis was supratentorial (cerebrum) or infratentorial (cerebellum) or both, were available for 195 patients [ 20 , 28 , 31 , 49 , 55 , 72 , 75 , 87 , 88 , 90 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 112 , 113 , 114 , 117 , 118 , 119 , 120 , 121 , 122 , 124 , 125 , 126 , 127 , 128 , 131 ]. Most of the BMs were located in the supratentorial region (cerebrum; 143/195 (73.3%) patients); in 50/195 (25.6%) and 12/195 (6.2%) patients, the BMs were in the infratentorial region (cerebellum) and in both sites, respectively.…”

Section: Endometrial Cancermentioning

confidence: 99%

“…The type of BMs with regard to the presence of extracranial metastases was available for 770 patients [20,28,31,37,49,53,62,63,74,75,84,[117][118][119][120][121][122][123][124][125][126][127][128]131], and extracranial metastases were seen in 346/770 (45.0%) of patients, whereas 424/770 (55.0%) patients had no extracranial metastases. Information on whether the metastasis was a single or multiple BMs was available for 411 patients [28,31,37,49,53,62,63,74,75,87,88,90,[92][93][94][95][96][97][98][99][100][101][102][103]…”

Section: Clinical Presentation and Diagnosismentioning

confidence: 99%

See 3 more Smart Citations

Brain Metastases from Uterine Cervical and Endometrial Cancer

Kato¹,

Tanase²,

Uno³

et al. 2021

Cancers

View full text Add to dashboard Cite

Reports on brain metastases (BMs) from uterine cervical carcinoma (CC) and uterine endometrial carcinoma (EC) have recently increased due to the development of massive databases and improvements in diagnostic procedures. This review separately investigates the prevalence, clinical characteristics, clinical presentation, diagnosis, treatment, and prognosis of BMs from CC and uterine endometrial carcinoma EC. For patients with CC, early-stage disease and poorly differentiated carcinoma lead to BMs, and elderly age, poor performance status, and multiple BMs are listed as poor prognostic factors. Advanced-stage disease and high-grade carcinoma are high-risk factors for BMs from EC, and multiple metastases and extracranial metastases, or unimodal therapies, are possibly factors indicating poor prognosis. There is no “most effective” therapy that has gained consensus for the treatment of BMs. Treatment decisions are based on clinical status, number of the metastases, tumor size, and metastases at distant organs. Surgical resection followed by adjuvant radiotherapy appears to be the best treatment approach to date. Stereotactic ablative radiation therapy has been increasingly associated with good outcomes in preserving cognitive functions. Despite treatment, patients died within 1 year after the BM diagnosis. BMs from uterine cancer remain quite rare, and the current evidence is limited; thus, further studies are needed.

show abstract

Section: Endometrial Cancermentioning

confidence: 99%

Section: Endometrial Cancermentioning

confidence: 99%

Section: Endometrial Cancermentioning

confidence: 99%

Section: Clinical Presentation and Diagnosismentioning

confidence: 99%

See 2 more Smart Citations

Brain Metastases from Uterine Cervical and Endometrial Cancer

Kato¹,

Tanase²,

Uno³

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Reports concerning patient suffering from endometrial malignancy with brain metastases ranged from 1975 to 2019 [6][7][8]11,[13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. The research yielded 117 articles, and 108 after exclusion of duplicated works.…”

Section: Database Researchmentioning

confidence: 99%

Brain metastases in endometrial cancer: A systematic review of the surgical prognostic factors

Beucler

Sellier

Corvilain

et al. 2021

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Context: although endometrial cancer is the fourth most common malignancy in women, dissemination to the brain is an exceptional event in the course of the disease. The aim of this review is to determine the important surgical prognostic factors for patients with endometrial cancer metastatic to the brain.Materials and methods: report of two cases. Medline database was used to conduct a systematic literature review from inception to December 2020 looking for Englishlanguage articles focused on brain metastases from endometrial cancer Results: the research yielded 108 articles, among which 23 articles were retained for a total of 87 patients. Mean age was 60 years-old ±11 at the time of diagnosis of endometrial cancer, and most of the tumors were aggressive (grade 3) with an advanced-stage disease (FIGO III, IV). At the time of diagnosis of cerebral disease, a single brain metastasis (p < 0.0001) and no extra-cerebra metastatic site (p = 0.0011) were significant good prognostic factors for the median overall survival. Surgical excision of brain metastasis followed by radiotherapy provided the longest median overall survival compared to radiotherapy and/or chemotherapy, and surgery alone (respectively 32, 5.4 and 4.8 months, p < 0.0001). An age of 60-year-old or less was not associated with a better prognosis. Conclusion:This review confirms that surgical excision followed by radiotherapy is a reliable option in patients with a single brain metastasis from endometrial cancer and no extra-cerebral metastatic site. This work could help to adapt the Graded Prognostic Assessment for brain metastases in endometrial cancer.

show abstract

Brain Metastasis in Papillary Serous Adenocarcinoma of the Endometrium

Filho

Fé

Rodrigues

et al. 2019

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

Background Most endometrial cancers (75%) are diagnosed in early stages (stages I and II), in which abnormal uterine bleeding is the most frequent clinical sign. When the diagnosis is performed in stage IV, the most common sites of metastasis are the lungs, liver and bones. Central nervous system (CNS) metastasis is a rare condition. The aim of this study is to describe a case of uterine papillary serous adenocarcinoma of the endometrium that progressed to brain and bone metastases. Case Report We present the case of a 56-year-old woman with abnormal uterine bleeding and endometrial thickened echo (1.8 cm). A hysteroscopy with biopsy was performed, which identified poor differentiated serous adenocarcinoma of the endometrium. A total abdominal hysterectomy, with pelvic and para-aortic lymphadenectomy, was performed. Analysis of the surgical specimen revealed a grade III uterine papillary serous adenocarcinoma. Adjuvant radio/chemotherapy (carboplatin and paclitaxel—six cycles) was indicated. Sixteen months after the surgery, the patient began to complain of headaches. Brain magnetic resonance imaging demonstrated an expansile mass in the right parietal lobe, suggesting a secondary hematogenous implant subsequently confirmed by biopsy. She underwent surgery for treatment of brain metastasis, followed by radiotherapy. She died 12 months after the brain metastasis diagnosis due to disease progression. Conclusion Uterine papillary serous adenocarcinoma of the endometrium has a low propensity to metastasize to the brain. To the best of our knowledge, this is the fifth documented case of uterine papillary serous adenocarcinoma of the endometrium with metastasis to the CNS.

show abstract

Métastase cérébrale d’un cancer de l’endomètre: à propos d’un cas et une revue de la littérature

Cited by 4 publications

References 13 publications

Brain Metastases from Uterine Cervical and Endometrial Cancer

Brain Metastases from Uterine Cervical and Endometrial Cancer

Brain metastases in endometrial cancer: A systematic review of the surgical prognostic factors

Brain Metastasis in Papillary Serous Adenocarcinoma of the Endometrium

Contact Info

Product

Resources

About